Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Update

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the target of a significant decrease in short interest in the month of June. As of June 15th, there was short interest totaling 17,654 shares, a decrease of 55.4% from the May 31st total of 39,619 shares. Based on an average daily volume of 100,034 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are sold short.

Otsuka Price Performance

Otsuka stock opened at $33.48 on Wednesday. The firm has a market capitalization of $35.96 billion and a P/E ratio of 14.13. Otsuka has a one year low of $21.68 and a one year high of $37.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The business has a fifty day moving average price of $34.45 and a 200-day moving average price of $32.68.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. The company had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, equities research analysts forecast that Otsuka will post 1.98 EPS for the current year.

Analyst Ratings Changes

Separately, Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.